OnProcess and Baxter Planning Forge Strategic Product and Commercial Partnership
14.7.2022 16:57:00 EEST | Business Wire | Press release
OnProcess Technology (www.onprocess.com), a global pioneer powering the world’s circular service supply chains, today announced the formation of a new strategic commercial and product partnership with Baxter Planning (www.baxterplanning.com). The partnership includes joint investment in the two companies’ technology roadmaps, a commitment to integrating certain product offerings, and a combined commercial approach.
The partnership is in response to what both companies see as growing industry calls to deliver and manage best-in-class service supply chains. As a result of several macroeconomic factors - global supply chain uncertainties, growing demand for sustainable practices, increasing e-waste legislation, the continued move to servitization, as well as higher cost of goods driven by rising interest rates and inflation - both companies cite that there has never been more focus on the role that the service supply chains play.
OnProcess and Baxter Planning have aligned views around the need to speed up the digitalization across the three main functions of the service supply chain:
- Planning (ensuring inventory levels are available in the right places to meet service-level commitments/SLAs)
- Delivering (ensuring inventory is delivered efficiently, to customers or other end-users, according to SLAs) and
- Recovering (ensuring that the maximum value is recovered from assets no longer required in the field, whether that inventory is unused, in need of repair/refurbishment/recycling, or for warranty recovery)
And putting Customer Experience at the heart of the service event.
The two companies recognize that to solve the complexities of the service supply chain requires a foundation built on aggregated data, and a platform that integrates and gathers that data from otherwise siloed operational sources. Only then can the three functional areas of Planning, Delivery and Recovery fully work together and provide a seamless view of the whole service supply chain. This results in smarter decisions, frictionless customer experiences, and a circular model that helps drive towards sustainability goals and targets.
With Baxter’s long-established record as a leader in the inventory planning market, and OnProcess’s reputation as a full-service provider to some of the world’s most recognised brands, the two companies have committed to further integrating their respective product offerings, such as Baxter Planning’s Prophet for service parts planning, and OnProcess’s Agora platform.
“We are excited to announce this very strategic partnership with Baxter,” said Oliver Lemanski, CEO, OnProcess. “Their deep domain expertise in service inventory planning, along with their market-leading software products, makes a natural fit with OnProcess, and in particular our technology platform Agora. We are on a mission to power the world’s circular service supply chains across a seamless process flow of Planning, Delivery and Recovery, and to do that we welcome partnerships, such as this with Baxter, to help us deliver on our promise . ”
“OnProcess has an enviable reputation in the service supply chain market, with some of the world’s most recognized brands as their clients,” stated Chuck Moeling, CEO, Baxter Planning. “As a best-of-breed planning provider, we see only synergy with OnProcess’s focus on Delivery and Recovery. We look forward to deepening our relationship and further developing our respective products so we can provide our mutual customers the very best the market has to offer . ”
About OnProcess Technology, Inc.
OnProcess supplies technology and services that power the world’s circular service supply chains. Delivering through the Agora™ platform, OnProcess streamlines processes, maximizes customer lifetime value, and improves ‘circular’ sustainability goals for many of the world’s leading computer, networking, med-tech, wireless, telecommunications, and IT companies. For more information please visit www.onprocess.com.
About Baxter Planning
Founded in 1993, Baxter Planning was built expressly for the service supply chain. Their software is developed based on proven best practices, industry expertise, and a partnership with customers to automate inventory planning. Their Total Cost Optimization methodology replaces spreadsheets and manual processes to deliver the best service level at the lowest possible cost. As a worldwide leader in Service Supply Chain software, Baxter Planning helps customers plan billions in service parts inventory every day. For more information, visit http://www.baxterplanning.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005079/en/
Contact information
Marta Marinova
OnProcess Technology, Inc.
mmarinova@onprocess.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
